To meet the need for high-viability isolation of sensitive and difficult cell types such as ATII cells, LevitasBio developed the LeviCell™ system – a powerful, label-free cell sorting platform to gently, rapidly, and efficiently separate and enrich cells.
Since the demand for heart transplantation far exceeds the available supply, cell-based cardiac repair therapies are being aggressively pursued as a more pragmatic, cost-effective, and low-risk option. However, despite the decades-long studies performed on cardiomyocytes, this cell type remains one of the more challenging to isolate. The LeviCell offers a real and immediate solution.
The LeviCell platform is an all-in-one system designed to run the LeviCell disposable cartridge for label-free cell separation applications. The system includes control and analysis software and imaging.
Rapid progress in the Single-cell analysis technologies field is necessary for the continued transformation of how we learn about and approach the clinical research, diagnosis, prognosis, and treatment of a wide range of disease types.
As scientists and researchers working with macrophages in vitro know all too well, the promise of new and powerful insights in science that these key cell types offer come at a price of time, frustration, and challenges in reproducing results.
Cell sorting and separation technologies are ubiquitous in molecular biology labs. Their popularity belies the serious limitations these tools have. For instance, flow cytometry requires antibody selection and therefore does not allow for a holistic look at a cellular population.
Magnetic levitation is dependent on many aspects of system and assay design. The LeviCell system has been designed to provide maximum flexibility to customers exploring new applications. Therefore, understanding the parameters that provide such flexibility is important to experimental design and outcome.